EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine

Sabina Pozzi, Ronit Satchi-Fainaro

Advanced Drug Delivery Reviews · 2024-06 · 209 · 115318

DOI: 10.1016/j.addr.2024.115318 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2024-06. Verfasst von Sabina Pozzi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel. Hauptthemen laut MEDLINE: Receptors, CCR2, Neoplasms, Inflammation, Chemokine CCL2. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 104 Literaturangaben. Gefördert von: European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The communication between cells and their microenvironment represents an intrinsic and essential attribute that takes place in several biological processes, including tissue homeostasis and tissue repair. Among these interactions, inflammation is certainly a central biological response that occurs through cytokines and the crosstalk with their respective receptors. In particular, the interaction between CCL2 and its main receptor, CCR2, plays a pivotal role in both harmful and protective inflammatory states, including cancer-mediated inflammation. The activation of the CCL2/CCR2 axis was shown to dictate the migration of macrophages with immune-suppressive phenotype and to aggravate the progression of different cancer types. In addition, this interaction mediates metastasis formation, further limiting the potential therapeutic outcome of anti-cancer drugs. Attempts to inhibit pharmacologically the CCL2/CCR2 axis have yet to show its anti-cancer efficacy as a single agent, but it sheds light on its role as a powerful tool to selectively alleviate pro-tumorigenic and anti-repair inflammation. In this review, we will elucidate the role of CCL2/CCR2 axis in promoting cancer inflammation by activating the host pro-tumorigenic phenotype. Moreover, we will provide some insight into the potential therapeutic benefit of targeting the CCL2/CCR2 axis for cancer and inflammation using novel delivery systems, aiming to sensitize non-responders to currently approved immunotherapies and offer new combinatory approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR2NeoplasmsInflammationChemokine CCL2NanomedicineHumansAnimalsTumor MicroenvironmentAntineoplastic AgentsDrug Delivery Systems

Stichwörter der Autor:innen

CCL2/CCR2 axisCancerDrug delivery systemsImmune cellsInflammation

Substanzen

Receptors, CCR2Chemokine CCL2Antineoplastic AgentsCCR2 protein, humanCCL2 protein, human

Autor:innen und Institutionen

  • Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; Sagol School of Neurosciences, Tel Aviv University, Tel Aviv 6997801, Israel. Electronic address: ronitsf@ta…

Förderung

  • European Research Council

Zitieren

APA

Pozzi, S., & Satchi-Fainaro, R. (2024). The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine. Advanced Drug Delivery Reviews, 209, 115318. https://doi.org/10.1016/j.addr.2024.115318

Vancouver

Pozzi S, Satchi-Fainaro R. The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine. Advanced Drug Delivery Reviews. 2024;209:115318. doi:10.1016/j.addr.2024.115318

BibTeX
@article{Pozzi2024,
  author = {Pozzi, Sabina and Satchi-Fainaro, Ronit},
  title = {The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine},
  journal = {Advanced Drug Delivery Reviews},
  year = {2024},
  volume = {209},
  pages = {115318},
  doi = {10.1016/j.addr.2024.115318}
}
Kostenlos starten →